

INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF
NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED

Report on the Audit of the Special Purpose Restated Interim Financial Statements**Opinion**

We have audited the accompanying Special Purpose Restated Interim Financial Statements of NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED ("the Company"), which comprise the Balance Sheet as at 30th September, 2021, the Statement of Profit and Loss (including Other Comprehensive Income) for the period 1st April 2021 to 30th September 2021, the Statement of Changes in Equity and the Statement of Cash Flows for the period then ended, and notes to the Special Purpose Restated Interim Financial Statements, including a summary of significant accounting policies and other explanatory information. The Special Purpose Restated Interim Financial Statements have been prepared by the Management of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant Rules issued thereunder for the purpose of preparation of the consolidated special purpose interim financial statements of Fabindia Limited (formerly known as Fabindia Private Limited and Fabindia Overseas Private Limited), which is having control over the Company (through its subsidiary Organic India Private Limited) and not to report on the Company as a separate entity.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Special Purpose Restated Interim Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 30th September, 2021, its loss including other comprehensive income, changes in equity and its cash flows for the period ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Special Purpose Restated Interim Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Special Purpose Restated Interim Financial Statements under the provisions of the Act and Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Restriction on Distribution and Use

The Special Purpose Restated Interim Financial Statements are prepared to assist Fabindia Limited (formerly known as Fabindia Private Limited and Fabindia Overseas Private Limited), which is having control over the Company (through its subsidiary Organic India Private Limited) in preparation of its consolidated special purpose interim financial statements and not to report on the Company as a separate entity.

Our report is intended solely for the use of Board of Directors for the above purpose and should not be distributed to or used by any other parties. We shall not be liable to the Company or to any other concerned for any claims, liabilities or expenses relating to this assignment. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.



Responsibilities of Management and Those Charged with Governance for the Special Purpose Restated Interim Financial Statements

The management is responsible for the preparation of these Special Purpose Restated Interim Financial Statements that give a true and fair view of the financial position, financial performance including other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Act, read with the relevant Rules issued thereunder.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Special Purpose Restated Interim Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Special Purpose Restated Interim Financial Statements, the management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of Special Purpose Restated Interim Financial Statements

Our objectives are to obtain reasonable assurance about whether the Special Purpose Restated Interim Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Special Purpose Restated Interim Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Special Purpose Restated Interim Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Special Purpose Restated Interim Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's



report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Special Purpose Restated Interim Financial Statements, including the disclosures, and whether the Special Purpose Restated Interim Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For Lodha & Co,
Chartered Accountants
Firm Registration Number: 301051E


(Gaurav Lodha)

Partner

Membership No.: 507462

UDIN: 21507462AAABEK4503

Place: New Delhi

Dated: 13/12/2021



NUTRIWEL HEALTH (INDIA) PVT. LTD.
BALANCE SHEET AS AT SEPTEMBER 30, 2021

(Amounts in ₹)

	Particulars	Note No.	Figures as at the Current Period 30th September 2021	Figures as at the Current Period 31st March 2021	Figures as at the Previous Period 31st March 2020	Figures as at the Previous Period 31st March 2019
	ASSETS					
1	Non-current assets					
a	Property, Plant and Equipment	2a	64,84,101	15,23,021	59,60,280	20,13,103
b	Intangible assets	2b	93,282	1,05,711	1,34,549	64,539
c	Intangible assets under Development	2c	3,06,82,553	2,49,01,066	1,24,44,684	39,95,642
d	Deferred tax assets (net)	2d	53,15,012	51,26,302	37,96,476	43,34,482
2	Current assets					
a	Inventories	3	18,67,356	47,03,390	36,59,022	34,15,347
b	Financial Assets					
i)	Trade receivables	4	2,07,437	2,68,864	4,29,507	9,45,043
ii)	Cash and cash equivalents	5a	77,47,908	1,18,56,817	6,64,19,525	9,59,69,710
iii)	Other Bank balances	5b	2,61,42,888	3,48,19,469	1,96,85,121	2,47,11,600
iv)	Other financial assets	6	14,58,760	16,78,958	12,96,757	16,69,161
c	Other current assets	7	52,99,189	62,25,805	64,91,780	41,89,421
	Total Assets		8,52,98,485	9,12,09,403	12,03,17,701	14,13,08,048
	EQUITY AND LIABILITIES					
1	EQUITY					
a	Equity Share Capital	8	2,11,710	2,11,710	2,11,710	2,11,710
b	Other Equity	9	-11,33,58,073	-9,37,64,479	-5,79,65,892	-2,13,19,277
2	LIABILITIES					
(i)	Non-current liabilities					
a	Financial Liabilities					
i)	Borrowings	10 (a)	11,90,86,230	11,90,86,230	11,90,86,230	11,90,86,230
ii)	Lease Liabilities	10 (b)	35,12,527	78,909	31,32,832	-
iii)	Other financial liabilities	11	2,55,48,891	2,07,12,686	1,07,98,757	11,52,772
b	Provisions	12	1,61,62,771	1,51,36,560	1,15,47,757	74,81,734
c	Deferred tax liabilities (Net)					
(ii)	Current liabilities					
a	Financial Liabilities					
i)	Borrowings	13 (a)	-	-	-	19,44,297
ii)	Lease Liabilities	13 (b)	18,49,460	-	13,77,742	-
iii)	Trade payables	13 (c)				
	(A) Total Outstanding dues of Micro and Small Enterprises		-	55,969	2,83,216	12,720
	(B) Total Outstanding dues of Creditors other than Micro and Small Enterprises		52,47,761	82,48,119	83,70,452	39,89,137
iv)	Other financial liabilities	14	1,09,18,770	95,14,497	89,77,466	96,25,462
b	Other current liabilities	15	1,49,11,961	1,08,88,598	1,37,88,568	1,86,12,592
c	Provisions	16	12,06,477	10,40,605	7,08,863	5,10,672
	Total Equity and Liabilities		8,52,98,485	9,12,09,403	12,03,17,701	14,13,08,048

The Accompanying notes form an integral part of the financial statements.
As per our report of even date

For Lodha & Co,
Chartered Accountants
Firm Regn. No. 301051E

Gaurav Lodha
Partner
M. No. 507462
Place: Delhi
Date: 13/12/2021



FOR AND ON BEHALF OF BOARD OF DIRECTORS
Nutriwel Health (India) Pvt. Ltd.

Dr. Shikha Nehru Sharma
DIN:-00174409

Mrs. Raj Sharma
DIN:-00186615



[Signature]

[Signature]

NUTRIWEL HEALTH (INDIA) PVT. LTD.
STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED SEPTEMBER 30, 2021

(Amounts in ₹)

Particulars	Note No.	For the Period 1st April 2021 to 30th September 2021	For the Period 1st April 2020 to 31st March 2021	For the Period 1st April 2019 to 31st March 2020	For the Period 6th March 2019 to 31st March 2019
I. Revenue From Operations	17	5,06,64,986	10,52,83,345	11,33,31,219	74,95,005
II. Other Income	18	8,40,803	29,53,170	87,64,266	8,06,568
III. Total Income (I+II)		5,15,05,788	10,82,36,515	12,20,95,485	83,01,573
IV. EXPENSES					
Cost of Contract Manufactured Goods	19	87,43,152	2,80,53,087	2,74,69,707	19,23,825
Changes in inventories of Finished Goods and Work-in-Progress	20	28,36,034	-10,44,367	-2,43,675	-9,79,678
Employee Benefit Expenses	21	3,05,28,626	6,26,20,508	7,25,79,173	73,27,041
Finance cost	22	55,88,170	1,07,52,049	1,13,36,214	12,80,858
Depreciation and amortization cost	2a, 2b	12,19,434	27,11,857	34,66,667	1,32,702
Other expenses	23	2,22,23,720	4,19,73,883	4,44,88,925	34,02,799
Total expenses		7,11,39,135	14,50,67,016	15,90,97,009	1,30,87,546
V. Profit/(loss) before exceptional items and tax (III-IV)		-1,96,33,347	-3,68,30,501	-3,70,01,524	-47,85,972
VI. Exceptional items		-	-	-	-
VII. Profit/(Loss) Before Tax (V+VI)		-1,96,33,347	-3,68,30,501	-3,70,01,524	-47,85,972
VIII. Tax Expense					
a. Current Tax					
b. Tax of earlier year provided / written back					
c. Deferred tax	24	-1,88,710	-13,29,825	5,38,005	-4,05,917
IX. Profit/(Loss) After Tax (VII-VIII)		-1,94,44,637	-3,55,00,675	-3,75,39,529	-43,80,055
X. Other Comprehensive Income					
Items that will be reclassified to (profit) or loss					
Remeasurement of defined benefit plans		1,48,956	2,97,912	-8,92,914	-17,361
Other Comprehensive Income/(Loss) for the year		1,48,956	2,97,912	-8,92,914	-17,361
XI. Total Comprehensive Income/(loss) for the year (IX+X)		-1,95,93,593	-3,57,98,587	-3,66,46,615	-43,62,694
XII. Earnings per Equity Shares of ₹ 10/- each					
- Basic/Diluted (in ₹)	25	-925.49	-1,690.93	-1,730.98	-206.07

The Accompanying notes form an integral part of the financial statements.
As per our report of even date

For Lodha & Co,
Chartered Accountants
Firm Regn. No. 301051E

Gaurav Lodha
Gaurav Lodha
Partner
M. No. 507462

Place: Delhi
Date: 13/12/2021



FOR AND ON BEHALF OF BOARD OF DIRECTORS
Nutriwel Health (India) Pvt. Ltd.

Dr. Shikha Nehru Sharma
Dr. Shikha Nehru Sharma
DIN:-00174409

Mrs. Raj Sharma
Mrs. Raj Sharma
DIN:-00186615



NUTRIWEL HEALTH (INDIA) PVT. LTD.
STATEMENT OF CASH FLOW FOR THE PERIOD ENDED SEPTEMBER 30, 2021

PARTICULARS	For the Period ended 30th September 2021	For the year ended 31st March 2021	ended 31st March 2020
A. CASH FLOW FROM OPERATING ACTIVITIES			
Profit / (Loss) Before Tax	-1,96,33,347	-3,68,30,501	-3,70,01,524
Adjustments for:			
Depreciation, amortization and impairment expenses	12,19,434	27,11,857	34,66,667
Remeasurement on defined benefit plans charged to OCI	-1,48,956	-2,97,912	8,92,914
Gain on Sale of Fixed Assets	-2,59,970	-	14,511
Finance Costs	55,88,170	1,07,52,049	1,13,36,214
Interest Income	-5,59,826	-25,10,496	-60,55,683
Operating Profit/(loss) before Working Capital changes	-1,37,94,495	-2,61,75,003	-2,73,46,901
(Increase) / Decrease in Trade Receivables	61,427	1,60,644	5,15,536
Increase / (Decrease) in Non Current financial liabilities- Provisions	10,26,211	35,88,802	40,66,023
Increase / (Decrease) in Current Liabilities Borrowings	-	-	-19,44,297
Increase / (Decrease) in Current Liabilities Lease Liabilities	34,33,618	-30,53,923	31,32,832
Increase / (Decrease) in Current Liabilities Lease Liabilities	18,49,460	-13,77,742	13,77,742
(Increase) / Decrease in Other Current assets	9,26,617	2,65,974	-23,02,358
(Increase) / Decrease in Current other financial assets	2,20,198	-3,82,201	3,72,404
(Increase)/Decrease in Inventories	28,36,034	-10,44,367	-2,43,675
Increase / (Decrease) in Trade Payables	-30,56,327	-3,49,580	46,51,812
Increase / (Decrease) in Other Current Financial Liabilities	14,04,274	5,37,031	-6,47,996
Increase / (Decrease) in Other Non Current Financial Liabilities	48,36,205	99,13,929	96,45,985
Increase / (Decrease) in Other Current Liabilities	40,23,363	-28,99,970	-48,24,024
Increase / (Decrease) in Current Provisions	1,65,872	3,31,742	1,98,191
Cash generated from/(used in) Operations before tax	39,32,457	-2,04,84,664	-1,33,48,727
Net Direct Taxes paid	-	-	-
Net cash flow from/(used in) Operating Activities	39,32,457	-2,04,84,664	-1,33,48,727
B. CASH FLOW FROM INVESTING ACTIVITIES			
Acquisition of Property, Plant & Equipment/ Intangible Assets including Capital Advances	-1,19,78,603	-1,07,02,142	-1,59,47,407
Proceeds from sale of Property, Plant & Equipment	2,89,000	-	-
Interest Received	5,59,826	25,10,496	60,55,683
Net cash flow from/(used in) Investing Activities	-1,11,29,777	-81,91,646	-98,91,724
Net cash from/(used in) Operating and Investing Activities	-71,97,321	-2,86,76,310	-2,32,40,451
C. CASH FLOW FROM FINANCING ACTIVITIES			
Finance Costs	-55,88,170	-1,07,52,049	-1,13,36,214
Net cash from/(used in) Financing Activities	-55,88,170	-1,07,52,049	-1,13,36,214
Net cash from/(used in) Operating, Investing & Financing Activities	-1,27,85,491	-3,94,28,359	-3,45,76,665
Effect of exchange differences on translation of foreign currency Cash & Cash equivalent	-	-	-
Net increase/(decrease) in Cash and Cash equivalent	-1,27,85,491	-3,94,28,359	-3,45,76,665
Opening balance of Cash and Cash equivalent	4,66,76,286	8,61,04,645	12,06,81,310
Closing balance of Cash and Cash equivalent	3,38,90,795	4,66,76,286	8,61,04,645
i) Cash on Hand	64,779	12,795	4,88,708
ii) Balance with Banks :			
- On Current Accounts	76,83,129	45,26,656	37,07,911
- Fixed Deposit	2,61,42,888	4,21,36,835	8,19,08,027
Total	3,38,90,795	4,66,76,286	8,61,04,645

As per our report of even date

For Lodha & Co,
Chartered Accountants
Firm Regn. No. 301051E

Gaurav Lodha
Gaurav Lodha
Partner
M. No. 507462
Place *Delhi*
Date: *13/12/2021*



FOR AND ON BEHALF OF BOARD OF DIRECTORS

Nutriwel Health (India) Pvt. Ltd.

Dr. Shikha Nehru Sharma
DIN:-00174409



Raj Sharma
Mrs. Raj Sharma
DIN:-00186615

I. Equity Share Capital

	Balance at the beginning of the current Reporting Period	Changes in Equity Share Capital ue to prior period errors	Restated balance at the beginning of the current reporting period	Changes during the period	End of Current Reporting Period	Balance at the End of the Reporting Period
Beginning of Reporting Period						
Current Reporting Period						
Balance as on 01st April, 2021	2,11,710	-	-	-	Balance as on 30th September 2021	2,11,710
Previous Reporting Period						
Balance as on 01st April, 2020	2,11,710	-	-	-	Balance as on 31st March, 2021	2,11,710
Previous Reporting Period						
Balance as on 01st April, 2019	2,11,710	-	-	-	Balance as on 31st March, 2020	2,11,710
Previous Reporting Period						
Balance as on 05th March, 2019	2,11,710	-	-	-	Balance as on 31st March, 2019	2,11,710

II. Other Equity		(Amounts in ₹)				
Particulars	Reserve & Surplus *		Other Comprehensive Income*			Total
	Securities Premium	Retained Earnings - Surplus in P/L Statement	Revaluation Reserve	Capital Reserve created as a result of Merger	Remeasurement of defined benefit liability/assets plans (Net of tax)	
Previous Reporting Period						
As on 05th March, 2019	11,98,87,873	-13,89,13,123		7,65,000		-1,82,60,250
Effect of business combination		13,03,669				13,03,669
Addition during the year						-
Profit for the year		-43,80,055				-43,80,055
Other Comprehensive Income (Net of Taxes)					17,361	17,361
As on 31st March, 2019	11,98,87,873	-14,19,89,509	-	7,65,000	17,361	-2,13,19,275
Addition during the year	-	-	-	-	-	-
Profit for the year	-	-3,75,39,531	-	-	-	-3,75,39,531
Other Comprehensive Income (Net of Taxes)	-	-	-	-	8,92,914	8,92,914
Previous Reporting Period						
As on 31st March, 2020	11,98,87,873	-17,95,29,040	-	7,65,000	9,10,275	-5,79,65,892
Addition during the year	-	-	-	-	-	-
Profit for the year	-	-3,55,00,675	-	-	-	-3,55,00,675
Other Comprehensive Income (Net of Taxes)	-	-	-	-	-2,97,912	-2,97,912
Previous Reporting Period						
As on 31st March, 2021	11,98,87,873	-21,50,29,715	-	7,65,000	6,12,363	-9,37,64,478
Addition during the year	-	-	-	-	-	-
Profit for the year	-	-1,94,44,637	-	-	-	-1,94,44,637
Other Comprehensive Income (Net of Taxes)	-	-	-	-	-1,48,956	-1,48,956
Current Reporting Period						
As on 30th September, 2021	11,98,87,873	-23,44,74,352	-	7,65,000	4,63,407	-11,33,58,070

As per our report of even date

For LODHA & CO.

Chartered Accountants

Firm registration number: 301051E

(Gaurav Lodha)
Partner

Membership No. 507462

Place: Delhi

Date: 13/12/2021

FOR AND ON BEHALF OF BOARD OF DIRECTORS
Nutriwel Health (India) Pvt. Ltd.Dr. Shikha Nehru Sharma
DIN:-00174409Mrs. Raj Sharma
DIN:-00186615

Handwritten signature/initials

NOTE - 1 COMPANY OVERVIEW, BASIS OF PREPARATION AND SIGNIFICANT ACCOUNTING POLICIES

1.1. Corporate and General Information

Nutriwel health India Private Limited (the 'Company') is a private company domiciled and incorporated in India on March 26th 2009 under the provisions of the Companies Act, 1956.

The Company is primarily engaged in the business of general medical consultancy aimed at weight loss, enhancement of health and fitness status, general wellbeing and improving the quality of life of individuals. The Company has its registered / corporate office located at 249 A, IInd Floor Okhla Industrial Estate Phase-III, New Delhi-110020.

1.2. Basis of preparation of Financial Statements

A. Statement of compliance:

The financial statements have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) (Amendment) Rules, 2016 and relevant provisions of the Companies Act, 2013.

The financial statements have been prepared in compliance of the requirement raised by FABINDIA Limited (formerly known as FABINDIA Private Limited and FABINDIA Overseas Private Limited), which is having control over the Company (through its subsidiary Organic India Private Limited) in preparation of its consolidated special purpose interim financial statements in pursuance of launching IPO.

B. Basis of preparation:

In accordance with the notification issued by the Ministry of Corporate Affairs, the company is required to prepare its financial statements as per the Indian accounting standards (IND AS) prescribed under Section 133 of Companies Act 2013 read with rule 3 of the companies (Indian Accounting Standards) rules, 2015 as amended by the companies (Indian Accounting Standards) amendment rules, 2016 with effect from April 1, 2017.

Accordingly, the company has prepared these Ind AS financial statements which comprises the Balance Sheet as at September 30, 2021, the Statement of Profit & Loss (including Other Comprehensive Income), the Statement of Changes in Equity & the Statement of Cash Flows for the period ended September 30, 2021 and a summary of the significant accounting policies and other explanatory information (together herein after referred to as " Ind AS financial statements").

C. Basis of Measurement

The Ind AS financial statements have been prepared on accrual basis following the historical cost convention, except for certain items that have been measured at fair value as required by the relevant IND AS.

The standalone Ind AS financial statements are presented in Indian Rupees (Rs.), which is the Company's functional and presentation currency.

Use of Estimates and Judgements

The preparation of financial statements in conformity with Ind AS requires that the management of the company makes estimates, assumptions and judgements that affect the reported amounts of income and expenses of the period, the reported balances of assets and liabilities and the disclosures relating to contingent liabilities as at the date of the financial statements. Actual results could differ from these estimates.

These estimates could change from period to period and also the actual results could vary from the estimates. Appropriate changes are made to the estimates as the management becomes aware of changes in circumstances



Shikha
R. Sharma

Nutriwel Health (India) Private Limited

Notes to financial statements

surrounding these estimates. The changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

D. Significant accounting policies:

I) Property, plant and equipment:

- a **Recognition & Measurement:** Property, Plant & Equipment's are stated at the cost of acquisition or construction, less accumulated depreciation and impairment losses, if any. The cost of an item of tangible asset comprises its purchase price, including import duties and other non-refundable taxes or levies and any attributable costs of bringing the asset to its working condition for its intended use. Any trade discount and rebates are deducted in arriving at the purchase price. Advances paid towards acquisition of Property, Plant & Equipment outstanding at each Balance Sheet date, are shown under non-current/current assets and cost of assets not ready for intended use before the period end, are shown as capital work-in-progress. Subsequent expenditure related to an item of tangible asset are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance. Expenditure during construction / erection period is included under capital work-in-progress and is allocated to the respective property, plant and equipment on completion of construction / erection.
- b **Depreciation:** Depreciation on property, plant and equipment has been provided using straight line method over their useful lives and in the manner prescribed under Schedule II of the Companies Act, 2013. The Company believes that the useful lives as taken is best represent the useful lives of assets based on internal assessment, where necessary which is different from the useful lives as prescribed under Part C of Schedule II of the Companies Act 2013. However, in respect of certain property, plant and equipment, depreciation is provided as per their useful lives as assessed by the management ranging from 3 to 15 years for plant and Leasehold development expenses is amortized over the primary period of lease. The cost and related accumulated depreciation are eliminated from the financial statements, upon sale and disposition of the assets and the resultant gains or losses are recognised in the statement of profit and loss. Further, The Input tax Credit is not claimed on purchase of Capital Assets, However Depreciation is charged on the Invoice value of such Asset.

II) **Intangible assets:**

Intangible assets comprise computer software, which are stated at cost less accumulated amortization and impairment losses, if any. The cost of an item of intangible asset comprises its purchase price, including import duties and other non-refundable taxes or levies and any attributable costs of bringing the asset to its working condition for its intended use. Any trade discount and rebates are deducted in arriving at the purchase price. Subsequent expenditure is capitalised only when it increases the future economic benefits from the specific asset to which it relates

Intangible assets are amortised over the useful economic life of the assets mentioned below: - Intangible assets are amortised over the expected duration of benefits. Such intangible assets are measured at cost less any accumulated amortisation and impairment losses, if any.

Particulars	Useful Life
Computer Software	5 Years



Nutriwel Health (India) Private Limited

Notes to financial statements

- III) **Lease:** The company has adopted Ind AS 116 "Leases" w.e.f 1st April 2019 and as a result of application of this standard to its leases, Company recognizes a "Right to Use Assets" and a corresponding "Lease Liability". The "Right to Use Assets" has been amortized and a finance cost has been charged for the same as per the requirements of Standard.
- IV) **Cash and cash equivalents:**
Cash and cash equivalents comprise cash on hand and demand deposits with banks which are short-term, highly liquid investments with original maturities of three months or less that are ready convertible into known amounts of cash and which are subject to insignificant risk of change in value.
- V) **Inventories:** Inventories are valued at lower of cost, or net realizable value. Cost of inventories includes in case of raw material, cost of purchase and incidental expenses incurred in bringing the inventories to their present location and condition; in case of work-in-progress, estimated direct cost and appropriate proportion; in case of finished goods, estimated direct cost and; and in case of traded goods, cost of purchase and other costs. Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.
- VI) **Employees Benefits:**
- a) **Short term employee benefits:** All employees' benefits payable wholly within twelve months rendering services are classified as short term employee benefits. Benefits such as salaries, wages, short-term compensated absences, performance incentives etc., and the expected cost of bonus, ex-gratia are recognised during the period in which the employee renders related service.
- b) **Defined Contribution Plans:** Contributions to the employees' regional provident fund, and Employees' State Insurance are recognised as defined contribution plan and charged as expenses during the period in which the employees perform the services.
- c) **Defined-benefit Plans:** Retirement benefits in the form of Gratuity are considered as defined benefit plan and determined on actuarial valuation using the Projected Unit Credit Method at the balance sheet date. The Company's gratuity scheme is a defined benefit plan. The present value of the obligation under such defined benefit plan is determined based on actuarial valuation using the Projected Unit Credit Method, which recognises each period of service as giving rise to additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation. The obligation is measured at the present value of the estimated future cash flows. The discount rates used for determining the present value of the obligation under defined benefit plans, is based on the market yields on Government securities as at the balance sheet date. Actuarial gain and losses are recognized in other comprehensive income which is not re classified to the statement of profit and loss in subsequent periods.
- d) **Other long term benefits:** The Company has provided for the liability at year end on account of including compensated absence as per the actuarial valuation as per the Projected Unit Credit Actuarial Method.
- VII) **Foreign currency transactions:** The functional currency of the company is Indian rupee. Foreign currency transactions are recorded at exchange rates prevailing on the date of transaction. Monetary assets and liabilities in foreign currencies as at the Balance Sheet date are translated at exchange rate prevailing at the year end. Exchange differences arising on actual payments / realisations and year end translations including on forward contracts are dealt with in Profit and Loss Statement.



Nutriwel Health (India) Private Limited

Notes to financial statements

VIII) **Income taxes:** Income tax is comprised of current and deferred tax. Income tax expense is recognised in the Statement of Profit and Loss, except to the extent it relates to items directly recognised in equity or in other comprehensive income.

- a **Current tax:** Current Tax is the amount of tax payable on the estimated taxable income for the current year as per the provisions of Income Tax Act, 1961.
- b **Deferred tax:** Deferred Tax is recognised for temporary differences. However, Deferred Tax Asset is recognised to the extent that, it is probable that taxable income will be available against which the same can be realised.

IX) **Provisions and contingencies:**

- a **Provisions:** Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate of the amount of the obligation. Provisions are reviewed at each reporting period and are adjusted to reflect the current best estimate.
- b **Contingencies:** A disclosure for contingent liability is made when there is possible obligation arising from past event the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made.

A disclosure for contingent assets is also made when there is possibility of an inflow of economic benefits to the entity which arise from unplanned or other unexpected events. Contingent liabilities and contingent assets are reviewed at each balance sheet date.

X) **Financial instruments:** A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

A. Financial assets:

Financial assets include cash and cash equivalents, trade and other receivables, investments in securities and other eligible current and non-current assets.

At initial recognition, all financial assets are measured at fair value. Such financial assets are subsequently classified under one of the following three categories according to the purpose for which they are held.

The classification is reviewed at the end of each reporting period:

(i) Financial asset carried at amortised cost

A financial asset is subsequently measured at amortised cost if it is held within business model whose objective is to hold the asset in order to collect contractual cash flow and the contractual term of the asset give rise on specified dates to cash flow that are solely payment of principal and interest on the principal amount outstanding.

(ii) Financial asset carried at Fair Value through other comprehensive income

A financial asset is subsequently measured at fair value through other comprehensive income if it is held within a business model whose objective is achieved by both collecting contractual cash flow and selling financial asset the contractual term of the asset give rise on specified dates to cash flow that are solely payment of principal and interest on the principal amount outstanding. For all other equity instrument, the company make irrevocable election to present in other comprehensive income subsequent change in fair value. The company makes such election on an instrument- to- instrument basis. If the company decides to classify an equity instrument through fair value through other comprehensive income, then all the fair value changes in the instrument excluding dividends are never recycled in OCI and are never recycled to statement of profit and loss, even on sale of the instrument.



Nutriwel Health (India) Private Limited

Notes to financial statements

(iii) Financial asset carried at Fair Value through Profit and loss

A financial asset which is not classified in any of the above category is subsequently measured at fair value through profit and loss.

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire or it transfers the financial asset and the transfer qualifies for derecognition under Ind AS 109.

- B. Financial liabilities:** Financial liabilities include long-term and short-term loans and borrowings, trade and other payables and other eligible current and non-current liabilities. All Financial liabilities are subsequently measured at amortised cost using the Effective interest method.

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires.

XI) Fair Value Measurement:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

For the purposes of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy in which they fall.


XII) Revenue recognition:

- a **Sales of Product:** Sales are recognised when the significant risks and rewards of ownership in the goods are transferred to the buyer as per the terms of the contract. Revenue includes excise duty and net of trade discounts, rebates, sales taxes goods and service tax, value added tax and applicable discounts and allowances.
- b **Sales of Services:** Revenue from maintenance services is recognized in terms of contractual stipulations on percentage completion basis provided no significant uncertainty exists regarding amount of the consideration and ultimate recovery is not doubtful.
- c **Interest income** from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is recognized on a time proportion basis taking into account the amount outstanding and using effective interest method.

The application of Ind AS 115 does not have any significant impact on recognition and measurement of revenue and related items in the financial statement.

- XIII) Earnings per share:** Earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Earning considered in ascertaining the Company's earnings per share is the net profit for the period and any attributable tax thereto for the period.

- XIV) Impairment:** The carrying amount of Property, plant and equipment, Intangible assets and Investment property are reviewed at each Balance Sheet date to assess impairment if any, based on internal / external



Nutriwel Health (India) Private Limited

Notes to financial statements

factors. An asset/Capital Generating Unit is treated as impaired, when the carrying cost of asset exceeds its recoverable value, being higher of value in use and net selling price. An impairment loss is recognised as an expense in the Statement of Profit and Loss in the year in which an asset is identified as impaired. The impairment loss recognised in prior accounting period is reversed, if there has been an improvement in recoverable amount.

1.4 Critical accounting estimates, assumptions and judgements

In the process of applying the Company's accounting policies, management has made the following estimates, assumptions and judgements, which have significant effect on the amounts recognised in the financial statement. Uncertainty about these assumptions and estimates could result in outcome that require a material adjustment to assets or liabilities affected in future periods.

i) Property, plant and equipment

Property, Plant and equipment represent at proportion of the asset base of the company. The useful lives and residual value of the company's asset are determined by the management at the time the asset is acquired and reviewed at each reporting date.

ii) Income taxes

The Company's tax jurisdiction is India. Significant judgements are involved in estimating budgeted profits for the purpose of paying advance tax, determining the provision for income taxes, including amount expected to be paid/recovered for uncertain tax positions.

iii) Contingencies

Management judgement is required for estimating the possible outflow of resources, if any, in respect of contingencies/claim/litigations against the Company as it is not possible to predict the outcome of pending matters with accuracy.

iv) Impairment of non-financial assets

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an assets or CGU's fair value less costs of disposal and its value in use. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

v) Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the Balance Sheet cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques, including the discounted cash flow model, which involve various judgements and assumptions.




2a PROPERTY, PLANT & EQUIPMENT

Amounts in ₹

Particulars	Furniture	Office Equipments	Computers	Motor Vehicle	Right to Use Asset (Ind AS 116)	Leasehold Improvements	Total
Gross carrying value							
As at March 5, 2019	3,85,090	21,90,926	80,93,520	23,24,254	-	77,77,351	2,07,71,141
Additions	12,390	-	-	-	-	-	12,390
Deductions/Disposals *	-	-	-	-	-	-	-
Balance at March 31, 2019	3,97,480	21,90,926	80,93,520	23,24,254	-	77,77,351	2,07,83,531
Additions	44,440	2,22,522	2,52,911	-	68,71,702	-	73,91,575
Deductions/Disposals *	-1,56,431	-1,67,762	-3,59,517	-	-	-	-6,83,710
Balance at March 31, 2020	2,85,489	22,45,686	79,86,914	23,24,254	68,71,702	77,77,351	2,74,91,396
Additions	-	67,777	3,08,746	-	-	-	3,76,523
Deductions/Disposals *	-	-	-	-	-21,30,763	-	-21,30,763
Balance at March 31, 2021	2,85,489	23,13,463	82,95,660	23,24,254	47,40,939	77,77,351	2,57,37,156
Additions	-	-	57,990	-	61,39,125	-	61,97,115
Deductions/Disposals *	-	-	-	-18,88,570	-	-	-18,88,570
Balance at September 30, 2021	2,85,489	23,13,463	83,53,650	4,35,684	1,08,80,064	77,77,351	3,00,45,701
Accumulated Depreciation & Amortisation Cost							
Balance at March 05th, 2019	2,57,856	19,47,048	72,51,601	21,90,762	-	69,92,358	1,86,39,624
Depreciation for the year	1,194	9,681	36,187	2,487	-	81,255	1,30,804
Deductions/Disposals	-	-	-	-	-	-	-
Balance at March 31st, 2019	2,59,050	19,56,729	72,87,788	21,93,249	-	70,73,613	1,87,70,428
Depreciation for the year	17,857	1,08,036	2,33,749	30,032	26,04,270	4,44,478	34,38,421
Deductions/Disposals	-1,51,812	-1,66,539	-3,59,382	-	-	-	-6,77,733
Balance at March 31, 2020	1,25,095	18,98,226	71,62,155	22,23,280	26,04,270	75,18,091	2,15,31,116
Depreciation for the year	17,016	94,507	3,79,168	20,900	23,16,562	99,062	29,27,215
Deductions/Disposals	-	-	-	-	-2,44,196	-	-2,44,196
Balance at March 31, 2021	1,42,111	19,92,733	75,41,323	22,44,180	46,76,636	76,17,152	2,42,14,135
Depreciation for the year	8,327	35,317	1,26,227	10,479	10,02,229	24,426	12,07,005
Deductions/Disposals *	-	-	-	-18,59,540	-	-	-18,59,540
Balance at September 30, 2021	1,50,438	20,28,050	76,67,550	3,95,119	56,78,865	76,41,579	2,35,61,600

Net carrying value

Balance at March 5, 2019	1,27,234	2,43,878	8,41,919	1,33,492	-	7,84,993	21,31,516
Balance at March 31, 2019	1,38,430	2,34,197	8,05,732	1,31,005	-	7,03,739	20,13,103
Balance at March 31, 2020	1,60,394	3,47,460	8,24,759	1,00,974	42,67,432	2,59,261	59,60,280
Balance at March 31, 2021	1,43,378	3,20,730	7,54,337	80,074	64,303	1,60,199	15,23,021
Balance at September 30, 2021	1,35,051	2,85,413	6,86,100	40,565	52,01,199	1,35,772	64,84,101



[Handwritten signature]

2b Intangible Assets

Particulars

Gross carrying value	Software	5,49,706
As at March 5, 2019		11,000
Additions		-
Deductions/Disposals *		
Balance at March 31, 2019		5,60,706
Additions		1,06,790
Deductions/Disposals *		-24,315
Balance at March 31, 2020		6,43,181
Additions		-
Deductions/Disposals *		
Balance at March 31, 2021		6,43,181
Additions		-
Deductions/Disposals *		
Balance at September 30, 2021		6,43,181
Accumulated Depreciation & Amortisation Cost		
Balance at March 05, 2019		4,94,269
Depreciation/Amortisation for the year		1,898
Deductions/Disposals		-
Balance at March 31, 2019		4,96,167
Depreciation/Amortisation for the year		28,246
Deductions/Disposals		-15,781
Balance at March 31, 2020		5,08,632
Depreciation/Amortisation for the year		28,838
Deductions/Disposals		-
Balance at March 31, 2021		5,37,470
Depreciation/Amortisation for the year		12,429
Deductions/Disposals		-
Balance at September 30, 2021		5,49,899
Net carrying value		
Balance at March 5, 2019		55,437
Balance at March 31, 2019		64,539
Balance at March 31, 2020		1,34,549
Balance at March 31, 2021		1,05,711
Balance at September 30, 2021		93,282



Signature

2C. Intangible Assets under development

Particulars	(Amounts in ₹)			
	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Intangible Assets under development	3,06,82,553	2,49,01,066	1,24,44,683	39,95,642
Total	3,06,82,553	2,49,01,066	1,24,44,683	39,95,642

Particulars	Amount in ₹			
	Amount in CWIP for a period of			
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 years
Projects in Progress				
As at 30th September, 2021	1,82,33,369	84,49,042	22,31,359	17,64,283
As at 31st March, 2021	1,24,56,382	84,49,042	22,31,359	17,64,283
As at 31st March, 2020	84,49,042	22,31,359		17,64,283
As at 31st March, 2019	22,31,359		17,64,283	
Total				

Notes:

* On transition date, the Company has opted to continue with carrying value of all of its property, plant and equipment as deemed cost. Gross block and accumulated amortisation from the previous GAAP have been disclosed for the purpose of better understanding of the original cost of assets.



[Handwritten signature]



3. Inventories

(as taken, valued and certified by management)

(valued at lower of cost or net realisation value)

(Amount in '₹')

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Finished Goods Manufactured	18,67,356	47,03,390	36,59,022	34,15,347
Total	18,67,356	47,03,390	36,59,022	34,15,347

4. Trade Receivables

(Amount in '₹')

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Considered Good				
Secured		-	-	
Unsecured	2,07,437	2,68,864	4,29,507	9,45,043
Unsecured which have significant increase in credit risk		-	-	
Credit impaired		-	-	
Total	2,07,437	2,68,864	4,29,507	9,45,043
Less: Allowance for Bad & Doubtful Debts		-	-	
Total	2,07,437	2,68,864	4,29,507	9,45,043



Handwritten signature



Handwritten signature

Trade Receivables Ageing Schedule

Particulars	Outstanding for following periods from due date of payments						Total
	Less than 6 Months	6 Months-1 Year	1-2 Years	2-3 Years	More than 3 Years		
Undisputed Trade Receivables - Considered Good							
As at 30th September, 2021	1,94,049	13,388	-	-	-		2,07,437
As at 31st March, 2021	2,65,035	3,829	-	-	-		2,68,864
As at 31st March, 2020	4,29,507	-	-	-	-		4,29,507
As at 31st March, 2019	9,39,548	-	5,495	-	-		9,45,043

Sharma

1/11/21



5a. Cash And Cash Equivalents

(Amount in '₹')

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Cash and Cash Equivalents				
- Balance with banks				
On Current Accounts	76,83,129	45,26,656	37,07,911	52,54,918
Cheque, Draft on Hand	-	-	-	-
- Cash on hand	64,779	12,795	4,88,708	2,49,742
- Fixed Deposit (maturity within 3 months)	-	73,17,366	6,22,22,906	9,04,65,050
Total	77,47,908	1,18,56,817	6,64,19,525	9,59,69,710

5b. Other Bank Balances

(Amount in '₹')

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
- Fixed deposits	2,61,42,888	3,48,19,469	1,96,85,121	2,47,11,600
Total	2,61,42,888	3,48,19,469	1,96,85,121	2,47,11,600

6. Other Financial Assets

(Amount in '₹')

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Security Deposit	8,01,569	9,05,369	11,53,348	9,46,120
Remittance in Payment Gateway	6,57,191	7,73,589	1,43,409	7,13,080
Advance recoverable in cash or kind or value to be received	-	-	-	9,962
Total	14,58,760	16,78,958	12,96,757	16,69,161

7. Other Current Assets

(Amount in '₹')

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Advance Tax (TDS)	12,34,081	18,46,815	15,54,508	12,10,955
Balance with Government Authorities	19,56,423	21,22,286	24,25,107	11,14,857
Prepaid Expenses	14,95,670	15,30,357	13,95,476	9,70,345
Accrued Interest on Fixed Deposit	1,97,936	2,33,341	8,02,832	6,36,696
Advance to Vendors	4,15,079	4,93,007	2,90,319	2,20,374
Advance to Staff	-	-	23,539	36,194
Total	52,99,189	62,25,805	64,91,780	41,89,421



Shruti

R. Sharma



8. Equity Share Capital
(i) Authorised, Issued, Subscribed and Paid up Share Capital

Share Capital	As at 30 September, 2021		As at 31 March, 2021		As at 31 March, 2020		As at 31 March, 2019	
	Number	Amount	Number	Amount	Number	Amount	Number	Amount
Authorised								
Equity Shares of ` 10 each	2,50,000	25,00,000	2,50,000	25,00,000	2,50,000	25,00,000	2,50,000	25,00,000
Compulsorily Convertible Preference Shares of ` 10 each	1,20,00,000	12,00,00,000	1,20,00,000	12,00,00,000	1,20,00,000	12,00,00,000	1,20,00,000	12,00,00,000
Total	1,22,50,000	12,25,00,000	1,22,50,000	12,25,00,000	1,22,50,000	12,25,00,000	1,22,50,000	12,25,00,000
Issued, Subscribed & Paid up								
Equity Shares of ` 10 each fully paid	21,171	2,11,710	21,171	2,11,710	21,171	2,11,710	21,171	2,11,710
Total	21,171	2,11,710	21,171	2,11,710	21,171	2,11,710	21,171	2,11,710

(ii) Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period

Particulars	As at 30 September, 2021		As at 31 March, 2021		As at 31 March, 2020		As at 31 March, 2019	
	Number	Amount	Number	Amount	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	21,171	2,11,710	21,171	2,11,710	21,171	2,11,710	21,171	2,11,710
Add: Issued during the year	-	-	-	-	-	-	-	-
Less: Buy back during the year	-	-	-	-	-	-	-	-
Shares outstanding at the end of the year	21,171	2,11,710	21,171	2,11,710	21,171	2,11,710	21,171	2,11,710

(iii) i. Terms / Rights attached to Equity Shares

The Company has one class of equity shares having a par value of `10 each. Each shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

(iv) Detail of shareholders holding more than 5% shares

Name of Shareholder	As at 30 September, 2021		As at 31 March, 2021		As at 31 March, 2020		As at 31 March, 2019	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding	No. of Shares held	% of Holding	No. of Shares held	% of Holding
Equity Shares:								
Onehealth Ventures Pte. Ltd.	9,609	45.4%	9,609	45.4%	9,609	45%	9,609	45%
Shikha Nehru Sharma	9,234	43.6%	9,234	43.6%	9,234	44%	9,234	44%
Organic India Pvt. Ltd.	2,328	11.0%	2,328	11.0%	2,328	11%	2,328	11%
Total	21,171	100%	21,171	100%	21,171	100%	21,171	100%

(v) No bonus, buy back and issue of shares other than in cash during preceding five years.



[Handwritten signature]

(vi) Shareholding of Promoters

As at 30th September 2021

Shares held by promoters at the end of the year			% change during the year
Promoter Name	No. of Shares	% of Total shares	
Dr. Shikha Nehru Sharma	9,234	43.62	0%
Onehealth Ventures Pte Ltd.	9,609	45.39	0%

As at 31st March 2021

Shares held by promoters at the end of the year			% change during the year
Promoter Name	No. of Shares	% of Total shares	
Dr. Shikha Nehru Sharma	9,234	43.62	0%
Onehealth Ventures Pte Ltd.	9,609	45.39	0%

As at 31st March 2020

Shares held by promoters at the end of the year			% change during the year
Promoter Name	No. of Shares	% of Total shares	
Dr. Shikha Nehru Sharma	9,234	43.62	0%
Onehealth Ventures Pte Ltd.	9,609	45.39	0%

As at 31st March 2019

Shares held by promoters at the end of the year			% change during the year
Promoter Name	No. of Shares	% of Total shares	
Dr. Shikha Nehru Sharma	9,234	43.62	18.10%
Onehealth Ventures Pte Ltd.	9,609	45.39	-3.60%

9. Other Equity

(Amounts in ₹)

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Security Premium				
Opening Balance	11,98,87,873	11,98,87,873	11,98,87,873	11,98,87,873
Addition During the year	-	-	-	-
Total	11,98,87,873	11,98,87,873	11,98,87,873	11,98,87,873

Capital Reserve created due to merger	7,65,000	7,65,000	7,65,000	7,65,000
--	----------	----------	----------	----------

Surplus

Opening balance	-21,44,17,354	-17,86,18,766	-14,19,72,149	-13,89,13,123
Effect of business combination	-	-	-	13,03,669
Net Profit/(Loss) for the year transferred from Statement of Profit & Loss	-1,94,44,637	-3,55,00,675	-3,75,39,531	-43,80,057
Other Comprehensive Income (Net of Taxes), if any	-1,48,956	-2,97,912	8,92,914	17,361
Total	-23,40,10,947	-21,44,17,354	-17,86,18,766	-14,19,72,149
Sub total	-11,33,58,073	-9,37,64,479	-5,79,65,892	-2,13,19,277

1) Capital reserve on business combination

During business combination, the excess of net assets taken over the cost of consideration paid are treated as capital reserve.

2) Securities premium represents the amount received in excess of par value of securities issued and conversion of Compulsorily Convertible Preference Shares into Equity Share by the company. This reserves is to be utilised/ to be utilised in accordance with the provisions of the act.




Shikha
R. Sharma

10 (a). Non Current Financial Liabilities: Borrowings

(Amounts in ₹)

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Unsecured Loan				
9% Optionally Convertible Debentures (1,19,08,623 No's of Optionally Convertible Debentures issued at a Face Value of Rs. 10 each)	11,90,86,230	11,90,86,230	11,90,86,230	11,90,86,230
Total	11,90,86,230	11,90,86,230	11,90,86,230	11,90,86,230



9% Optionally Convertible Debentures (OCD), the investor shall exercise either the conversion of OCD into Non-Convertible Debentures or will convert in Equity only after the completion of 3 years from the date of allotment, subject to Milestones and conditions mentioned in the Shareholders and Debentures Agreement. Further, the company considering the uncertain pandemic situation had requested its investors to extend the timeframe for completion of milestones for a period of 6(six) months from 28th February 2022 to 31st August 2022 and the same has been agreed upon & confirmed by the Investor. The Management is confident that it will achieve the milestones agreed.

10 (b). Non Current: Lease Liabilities

(Amounts in ₹)

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 20219
Lease Liability	35,12,527	78,909	31,32,832	-
Total	35,12,527	78,909	31,32,832	-

11. Non Current : Other Financial Liabilities

(Amounts in ₹)

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Interest Accrued on 9% Optionally Convertible Debentures	2,55,48,891	2,07,12,686	1,07,98,757	11,52,772
Total	2,55,48,891	2,07,12,686	1,07,98,757	11,52,772

12. Current Liabilities :Provisions

(Amounts in ₹)

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Provision for Gruity	99,35,146	97,73,294	88,71,791	56,90,251
Provision for Leave Encashment	62,27,625	53,63,266	26,75,966	17,91,483
Total	1,61,62,771	1,51,36,560	1,15,47,757	74,81,734

13 (a). Financial Liabilities: Borrowings

(Amounts in ₹)

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Loan and advance from Related Party*	-	-	-	19,44,297
Total	-	-	-	19,44,297

13 (b). Lease Liabilities


(Amounts in ₹)

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 20219
Lease Liability	18,49,460	-	13,77,742	-
Total	18,49,460	-	13,77,742	-

13 (c). Financial Liabilities: Trade Payables

(Amounts in ₹)

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Total outstanding dues of-				
-Micro and Small Enterprises	-	55,969	2,83,216	12,720
- Payable to related Party	51,56,776	76,55,273	80,74,659	-
-Other Payables	90,985	5,92,847	2,95,793	39,89,137
Total	52,47,761	83,04,088	86,53,668	40,01,857



Trade Payable Ageing Schedule

Particulars	Less than 1 year	1-2 Years	2-3 Years	More than 3 Years	Total
As at 30th September, 2021					
a). Micro & Small Enterprises	-	-	-	-	-
b). Others	52,47,761	-	-	-	52,47,761
Total	52,47,761	-	-	-	52,47,761
As at 31st March, 2021					
a). Micro & Small Enterprises	55,969	-	-	-	55,969
b). Others	82,48,119	-	-	-	82,48,119
Total	83,04,088	-	-	-	83,04,088
As at 31st March, 2020					
a). Micro & Small Enterprises	2,83,216	-	-	-	2,83,216
b). Others	83,70,452	-	-	-	83,70,452
Total	86,53,668	-	-	-	86,53,668
As at 31st March, 2019					
a). Micro & Small Enterprises	12,720	-	-	-	12,720
b). Others	39,89,137	-	-	-	39,89,137
Total	40,01,857	-	-	-	40,01,857



T. Kulkarni



R. Sharma

14. Other Financial Liabilities

(Amounts in ₹)

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Bonus Payable	5,41,267	4,26,919	2,20,543	17,78,064
Security Deposit Staff	5,77,690	1,16,531	2,34,558	65,042
Salary, wages & Incentives Payable	55,10,308	57,45,330	57,56,798	51,42,829
Other Payable	42,89,505	32,25,716	27,65,567	26,39,527
Total	1,09,18,770	95,14,497	89,77,466	96,25,462

15. Other Current Liabilities

(Amounts in ₹)

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Advance received from Customers	1,38,06,107	84,39,117	1,14,48,382	1,68,41,119
Statutory Dues Payable	11,05,854	24,49,481	23,40,186	17,71,472
Total	1,49,11,961	1,08,88,598	1,37,88,568	1,86,12,592

16. Provisions

(Amounts in ₹)

Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
- Provision for Grauity	6,91,895	6,31,728	5,11,394	3,66,565
- Provision for Leave Encashment	5,14,582	4,08,877	1,97,468	1,44,106
Total	12,06,477	10,40,605	7,08,862	5,10,672



Handwritten signature



Handwritten signature

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED

17. Revenue from operations

(Amounts in ₹)

Particulars	For the Period 1st April 2021 to 30th September 2021	For the Period 1st April 2020 to 31st March 2021	For the Period 1st April 2019 to 31st March 2020	For the Period 6th March 2019 to 31st March 2019
Sale of Services				
Medical Fees	2,46,04,424	5,24,55,522	6,64,07,068	59,13,385
Consultancy Fees	6,24,199	5,39,591	1,13,101	-
Nutrition SaaS	49,589	10,649	-	-
Academy	49,36,432	50,71,520	-	-
Blood Test Collection	13,29,582	37,44,766	42,01,688	1,24,534
Sale of Products				
Product Sales	1,91,20,760	4,34,61,296	4,26,09,362	14,57,086
Total	5,06,64,986	10,52,83,345	11,33,31,219	74,95,005

18. Other income

(Amounts in ₹)

Particulars	For the Period 1st April 2021 to 30th September 2021	For the Period 1st April 2020 to 31st March 2021	For the Period 1st April 2019 to 31st March 2020	For the Period 6th March 2019 to 31st March 2019
Interest Income				
-on Fixed Deposits	5,59,826	25,10,496	60,55,683	2,44,035
Other Non-Operational Income				
Profit on sale of Fixed Assets	2,59,970	-	-	-
Liabilities no longer required written back	-	-	23,76,007	5,54,780
Sale of Scrap	-	-	47,400	-
Misc Income	21,007	4,42,674	2,85,177	7,753
Total	8,40,803	29,53,170	87,64,266	8,06,568

19. Cost of Contract Manufactured Goods

(Amounts in ₹)

Particulars	For the Period 1st April 2021 to 30th September 2021	For the Period 1st April 2020 to 31st March 2021	For the Period 1st April 2019 to 31st March 2020	For the Period 6th March 2019 to 31st March 2019
Cost of Contract Manufactured Goods	87,43,152	2,80,53,087	2,74,69,707	19,23,825
Total	87,43,152	2,80,53,087	2,74,69,707	19,23,825

20. Changes in Inventory of Finished Goods and Work In Progress

(Amounts in ₹)

Particulars	For the Period 1st April 2021 to 30th September 2021	For the Period 1st April 2020 to 31st March 2021	For the Period 1st April 2019 to 31st March 2020	For the Period 6th March 2019 to 31st March 2019
Opening Stock	47,03,390	36,59,022	34,15,347	24,35,669
Less :- Closing Stock	18,67,356	47,03,390	36,59,022	34,15,347
Changes in Inventory of Finished Goods & WIP	28,36,034	-10,44,367	-2,43,675	-9,79,678



Handwritten signature/initials



Handwritten signature/initials

21. Employee Benefits Expenses

(Amounts in ₹)

Particulars	For the Period 1st April 2021 to 30th September 2021	For the Period 1st April 2020 to 31st March 2021	For the Period 1st April 2019 to 31st March 2020	For the Period 6th March 2019 to 31st March 2019
Salaries & Wages	2,76,79,136	5,69,17,997	6,40,03,977	28,79,155
Contribution to Provident and other funds	6,68,865	13,63,050	19,34,476	1,62,668
Leave Encashment Expense	15,10,040	47,78,721	12,88,031	7,36,922
Staff Welfare Expenses	45,318	91,168	8,36,754	98,612
Gratuity Expense	5,10,919	-7,36,804	42,95,392	16,71,620
Bonus	1,14,348	2,06,376	2,20,543	17,78,064
Total	3,05,28,626	6,26,20,508	7,25,79,173	73,27,041

22. Finance Cost

(Amounts in ₹)

Particulars	For the Period 1st April 2021 to 30th September 2021	For the Period 1st April 2020 to 31st March 2021	For the Period 1st April 2019 to 31st March 2020	For the Period 6th March 2019 to 31st March 2019
Interest on Debentures	53,73,562	1,07,17,761	1,07,17,761	12,80,858
Interest cost on Lease	2,14,608	34,288	6,18,453	-
Total	55,88,170	1,07,52,049	1,13,36,214	12,80,858

23. Other Expenses


(Amounts in ₹)

Particulars	For the Period 1st April 2021 to 30th September 2021	For the Period 1st April 2020 to 31st March 2021	For the Period 1st April 2019 to 31st March 2020	For the Period 6th March 2019 to 31st March 2019
Repair & Maintenance				
- Building	1,94,948	3,40,016	4,93,355	21,426
- Plant & Machinery	23,196	43,642	1,11,470	24,349
- Others	45,929	62,597	3,31,675	21,374
Consultancy Fees	15,000	94,435	92,025	22,500
Auditor remuneration and expenses	-	-	-	-
- Statutory Audit	1,40,000	2,80,000	3,68,500	3,55,000
- Tax Audit	30,000	60,000	60,000	60,000
- Other Matters	20,999	-	-	-
Auditor's Out of Pocket Expense	-	10,050	2,390	-
Appeal Filing Fees	-	-	-	10,000
Communication Expenses	28,70,531	59,49,206	67,01,674	4,40,492
Rent	-	-	-	-
- Building	1,87,561	9,38,620	1,90,000	2,34,600
- Office Equipment	1,27,847	2,94,640	3,17,858	26,264
Bank Charges	29,136	-11,031	30,167	32,147
Blood Test Expense	8,10,066	24,22,942	29,20,295	-
Gateway Collection Charges	6,76,782	10,23,507	11,83,620	1,00,906
Conveyance & Travelling	15,135	55,151	2,25,536	16,135
Electricity & Water Expenses	4,39,481	6,81,219	14,82,706	1,51,202
Insurance Expenses	1,83,627	4,01,599	2,87,234	19,050
Legal & Professional Expenses	36,74,684	8,92,255	8,72,015	6,000
Trademark fees & Brand/Logo Royalty	17,486	87,284	-	-
Yoga Training Expenses	1,06,956	1,27,423	-	-
Commission Paid	23,32,535	47,65,103	25,98,170	81,173
Loss from exchange fluctuation	92,215	79,626	24,309	2,355
Printing & Stationary	65,607	1,11,009	2,56,139	17,183
Business Promotion	67,120	44,866	2,86,967	19,680
Advertisement	48,96,595	1,11,84,984	1,41,83,633	8,84,444
Recruitment Expenses	50,000	1,09,758	91,218	-
Interest on Statutory Dues	8,537	2,417	1,942	-
Software & Website Maintenance Expenses	12,49,185	20,00,983	24,95,704	5,20,479
Security Charges	2,22,380	2,68,077	2,61,252	21,450
Office Expense	48,677	1,02,795	1,73,763	-
Rate & Taxes	332	12,342	1,56,994	9,811
Delivery Charges (Freight & Courier)	12,84,243	33,16,475	26,62,552	-1,44,009
Filing Fees	2,000	7,050	6,750	9,600
Misc. Expenses	58,257	3,44,977	1,94,261	8,683
Product Development Charges	-	-	8,612	8,504
Complimentary Kits	55,407	2,05,466	3,97,700	14,362
Cenvat Credit W/o	16,56,671	35,21,607	43,88,386	3,66,992
Study Material Expenses	2,15,221	1,36,090	-	-
Retainership Fee	-	13,12,200	-	-
Packing Material	3,09,375	6,94,504	6,15,542	40,648
Gain/Loss on sale of Fixed Assets	-	-	14,511	-
Total	2,22,23,720	4,19,73,883	4,44,88,925	34,02,799

25. EARNING PER SHARE

(Amounts in ₹)

Particulars	For the Period 1st April 2020 to 30th September 2021	For the Period 1st April 2020 to 31st March 2021	For the Period 1st April 2019 to 31st March 2020	For the Period 6th March 2019 to 31st March 2019
a) Profit for the year attributable to Equity Shareholders	-1,95,93,593	-3,57,98,587	-3,66,46,615	-43,62,694
b) Weighted average number of Equity Shares for Basic / Diluted EPS	21,171	21,171	21,171	21,171
c) Earnings per share of Rs. 10 each				
- Basic / Diluted	-925.49	-1,690.93	-1,730.98	-206.07



Handwritten signature/initials

Handwritten signature/initials

NUTRIWEL HEALTH (INDIA) PVT. LTD.

Financial Ratios

Sr No	Methodology	30th September, 2021	31st March, 2021	31st March, 2020	Variance
1	Current Ratio	1.25	2.00	2.92	-37% Current ratio declined due to reduced Cash and Cash Equivalent
2	Debt Equity Ratio	-1.28	-1.49	-2.25	14% Ratio increased due to decrease in shareholder's equity due to losses
3	Debt Service Coverage Ratio	-2.51	-2.43	-2.26	-4% Ratio decreased due to reduced EBIT due to losses
4	Return on Equity Ratio	17%	38%	63%	-55% Ratio reduced due to reduced shareholder's equity and Reduced PAT
5	Inventory Turnover Ratio	3.52	6.46	7.70	-45% Ratio decreased due to increase in inventory
6	Trade Receivables Turnover Ratio	212.74	301.51	164.90	-29% Increased due to increase in Avg Trade receivables
7	Trade Payable Turnover Ratio	1.71	3.19	4.30	-46% Ratio decreased due to reduced expenses
8	Net Capital Turnover Ratio	2.64	2.23	1.41	18% Ratio increased due to reduced Avg Working Capital
9	Net Profit Ratio	-38%	-33%	-30%	-15% Ratio decreased due to decrease in PAT
10	Return on Capital Employed	-25%	-35%	-27%	29% Ratio increased due to reduced Avg Capital Employed
11	Return on Investment		Not Applicable	Not Applicable	



Handwritten signature/initials



Handwritten signature/initials

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

26 Contingent Liabilities and Commitments (as certified by the management) –

Contingent Liabilities

a. Other money for which the company is contingently liable

Income Tax Matters Rs. 28,26,960/- towards A.Y. 2015-16 and A.Y. 2014-15 (Previous Year Rs. 28,26,960/-) :-
(Previous Year: ` Nil)

Capital and other Commitments Rs. Nil (Previous Year: ` Nil)

27 .

(A) The Scheme of Amalgamation

The Board of Directors of the Company "Nutriwel Health (India) Pvt Ltd." had approved a Scheme of Arrangement between "Nutriwel Health (India) Pvt Ltd." and "Dr Shikhas Nutri-Health Systems Pvt. Ltd" and their respective shareholders for amalgamation of "Dr Shikhas Nutri-Health Systems Pvt. Ltd" with "Nutriwel Health (India) Pvt Ltd." w.e.f 01.04.2019. Subsequent to the regulatory approval/sanctions, the Scheme has since been sanctioned by both the Hon'ble New Delhi Special Bench of the National Company Law Tribunal ("NCLT") vide Order dated 15th May, 2020. The Scheme became effective w.e.f. 24th June, 2020 on filing certified copy of Orders with the respective Registrar of Companies by the Companies and operative w.e.f. Appointed Date i.e., 01.04.2019. Accordingly, the effect of the said Scheme has been given in previous financial statements. Pursuant to the Scheme-

i. The difference between the assets and liabilities so recorded in the books of account of the Company (the Transferee Company or Nutriwel Health (India) Pvt Ltd.) as reduced by the aggregate face value of Equity Shares to be issued by the Company has been adjusted against balance Capital Reserve in the books of account of the Company:

Particulars- As on 01/04/2018 -	Amount in Rs.
Assets (A)	14,37,833
Liabilities	1,93,27,077
Reserves & Surplus	(1,87,39,244)
Total Liabilities (B)	5,87,833,
Total Liabilities (B) – Assets (A)	8,50,000
Cancellation On shares held by Transferee Company	85,000
Amount Transferred to Capital Reserve	7,65,000

ii. The Transferor company is a wholly owned subsidiary of the Transferee Company. Upon this scheme coming into effect, all Equity shares of the Transferor Company held by the Transferee company (either directly and/or through its nominees, shall stand cancelled. Also no new shares shall be issued or payment made in cash whatsoever by the Transferee Company in lieu of shares of the Transferor company.



Shikha

R. Shew

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

iii. All assets, liabilities and provisions of each of the amalgamating companies have been transferred to and vested in the company w.e.f. 01.04.2019 and have been recorded at book value of respective assets/liabilities under the "Pooling of Interest" method of accounting as per "Ind AS 103 – Business Combinations".

iv. Loans, advances and other obligations/liabilities due including Equity Shares held between the company and the amalgamating companies and vice versa and between the amalgamating companies *inter se* have been cancelled. Accordingly, 85000 Nos. Equity Shares of the Transferor Company held by the Transferee Company have been cancelled while reaching the Capital Reserve amount

v. Consequent to and as part of the amalgamation of the "Dr Shikhas Nutri-Health Systems Pvt. Ltd." (Transferor Companies) with the "Nutriwel Health (India) Pvt Ltd." (Transferee Company), the respective Authorised Share Capital of the Transferor Companies shall stand merged into and combined with the Authorised Share Capital of the Company pursuant to the Scheme, without any further act or deed, and without payment of any registration or filing fee on such combined Authorized Share Capital, the Transferor Companies and the Transferee Company having already paid such fees. Accordingly, Authorized Capital of the Company under the Scheme is to increase as detailed below:

Particulars	Amount in Rs.
2,50,000 Equity Shares of Rs. 10/- each	25,00,000
1,20,00,000 Compulsory Convertible Preference Share of Rs. 10/- each	12,00,00,000
Total Authorized Share Capital	12,25,00,000

vi. The necessary steps and formalities in respect of transfer of assets and investments in favour of the Company are under implementation.

vii. All business activities carried on by the "Dr Shikhas Nutri-Health Systems Pvt. Ltd." (Transferor Company) w.e.f. 01.04.2019 in the ordinary course of business were deemed to have been carried on for and on behalf of and in trust for the Company and consequently all profits and losses and related taxes paid were deemed to be the profits, losses and taxes of the Transferee Company, as the case may be.

viii. Since the above transaction results in a common control business combination, considering the requirements of Ind AS 103, the accounting for above transactions have been given effect retrospectively by the Company. Accordingly, the financial statements for the corresponding period in 2018-19 and year ended March 31, 2019 as well as the opening balances as of April 1, 2018 have been restated to give effect to the above Scheme.

(B) As the Scheme is effective from the Appointed Date i.e. 01.04.2019, the impact of result for the period for 01.04.2019 to 31.03.2020 have been disclosed/given in the Profit & Loss Statement, under the head "Reserve & Surplus" are:

Particulars for the period/year 2019-20	Amonut in Rs.
Total Revenue (including other income)	2,28,004.96
Total Expenses	2,27,710.70
Profit Before tax	293.65
Tax Expense (Including deferred tax)	-
Profit/(Loss) After Tax	293.65
Net Profit for the Year 2019-20	293.65



Shikha

R. Shem

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS


28 . Disclosure in accordance with IND AS-12 (Accounting for Taxes on Income) as prescribed under section 133 of Companies Act 2013 read with rule 7 of Companies (Accounts) Rules, 2014 :

Particulars	(Amount in Rs.)			
	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Deferred Tax Assets on account of:				
Provision for Leave Encashment	15,42,617	13,20,666	5,97,052	5,03,253
- Provision for Gratuity'	24,31,467	23,80,669	19,57,900	15,74,772
- Difference between book depreciation & tax depreciation	12,17,086	13,27,287	12,46,540	17,94,160
- Bonus Payable	1,23,842	97,679	-5,015	4,62,297
Total (A)	53,15,012	51,26,302	37,96,476	43,34,482
B. Deferred Tax Liabilities:				
- Difference between book depreciation & tax depreciation				
Total (B)				
Deferred Tax Assets/(Liabilities) (A-B)	53,15,012	51,26,302	37,96,476	43,34,482

The company has incurred losses in previous year and current year. Considering the prudence, deferred tax assets (net) on carried forward losses has not been recognized/considered necessary presently. However, in view of increase in business activity and increase in paid up capital, the management is confident about the realization of above deferred tax assets (net).

29. The details of amounts outstanding under the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act) to the extent of information available with the Company are as under:

		(Amount in Rs.)			
S.No	Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
(a)	Principal amount remaining unpaid	57,058	-	2,83,216	12,720
(b)	Principal amount overdue	7,798	-	1,05,866	-
	Interest due thereon	-	-	-	-
(c)	Interest paid by the Company in term Section 16 of MSMED Act	-	-	-	-
	Payment made to the supplier beyond appointed day during the Year	-	-	-	-
(d)	Interest due and payable for the period of in making payment (which have been paid bu beyond the appointed day during the year) but without adding the interest specified	-	-	-	-
(e)	Interest accrued and remaining unpaid.	-	-	-	-
(f)	Further Interest remaining due and pay even in the succeeding years, until such when the interest due as above are actually paid to the small enterp	-	-	-	-



Handwritten signature

Handwritten signature

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

30. Auditor's Remuneration: (Excluding Taxes)

(Amount in Rs.)

S. No.	Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
(a)	Statutory Audit Fees	1,40,000	2,80,000	3,68,500	3,55,000
(b)	Tax Audit	30,000	60,000	60,000	60,000
(c)	Certification Work/ Other Services	20,999	-	-	-
(d)	Reimbursement of expenses	-	-	-	-
	Total	1,90,999	3,40,000	4,28,500	4,15,000

31. Expenditure in Foreign Exchange:

(Amount in Rs)

S. No.	Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
(a)	Gateway Collection Charges	88,946	66,485	54,572	4,084
(b)	Digital Advertisement	63,763	-	-	-
	Total	1,52,709	66,485	54,572	4,084

32. Earning in Foreign Exchange (on accrual basis):

(Amount in Rs)

S. No.	Particulars	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
(a)	Medical Consultancy Fees	39,97,856	1,45,87,524	82,60,981	62,731
(b)	Academy fees	1,40,807	5,51,600	-	-
(c)	8Well Software Subscription	1,500	-	-	-
	Total	41,40,163	1,51,39,124	82,60,981	62,731

33. Prior Period Expenses of Rs. Nil (PY Rs. Nil) include Salary & Wages Nil (PY Rs. Nil) and Gratuity Expense Nil (PY Rs. Nil).

34. Related Party Disclosers (as identified and disclosed by the management)

i. Name of the Related Parties and nature of relationship

a. Key Managerial Personnel & their Relatives

- 1) Raj Sharma, Whole time Director
- 2) Shikha Nehru Sharma, Managing Director
- 3) Amit Sharma, Relative of Managing Director
- 4) Nisha , Company Secretary
- 5) Mr. Sudhir Maheshwari, Director
- 6) Ms. Sangeeta Maheshwari, Director
- 7) Mr. Abhinandan Madhukarrao Dhoke, Director (ceased from 8th October, 2020)
- 8) Mr. Vikash, Director (Joined from 18th November, 2020)
- 9) Mr. Saurabh Tiwari, Director

b. Other related parties where control exists



Shikha

Raj Sharma

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

- 1) Wellness Products
- 2) Wellness Diabetacare Pvt. Ltd.

c. Other related parties having control on Nutriwel Health India Pvt Ltd

- 1) Organic India Pvt Ltd

ii. Transactions with Related Parties:

(Amount in Rs)					
Particulars	Year	Key Management Personnel and their Relatives	Subsidiary Company	Other Entities	Total
Remuneration Paid : - Key Managerial Person	2021-22 (Sept)	10,62,000	-	-	10,62,000
	2020-21	(44,64,000)	-	-	(44,64,000)
	2019-20	(80,04,000)			(80,04,000)
	2018-19	(6,67,000)			(6,67,000)
Organic India Pvt. Ltd. (during the year)					
Purchase				87,43,152 (2,78,92,087) (2,72,51,033) (21,22,756)	87,43,152 (2,78,92,087) (2,72,51,033) (21,22,756)
Medical Consultancy				1,97,683 (5,27,231) (6,97,719) (1,10,544)	1,97,683 (5,27,231) (6,97,719) (1,10,544)
Interest on Debentures				53,73,562 (1,07,17,761) (1,07,17,761) (12,80,858)	53,73,562 (1,07,17,761) (1,07,17,761) (12,80,858)
Freight Reimbursement				4,12,172 (12,35,415) (14,68,847) (4,19,431)	4,12,172 (12,35,415) (14,68,847) (4,19,431)
Professional fee Reimbursement				Nil (Nil) (1,25,000) (Nil)	Nil (Nil) (1,25,000) (Nil)



Handwritten signature/initials

Handwritten signature/initials

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

Store Rent				Nil (Nil) (30,000) (Nil)	Nil (Nil) (30,000) (Nil)
Royalty				(Nil) (55,784) (16,597) (Nil)	(Nil) (55,784) (16,597) (Nil)

iii. Balance Outstanding at the Year end.

(Amount in Rs)

Particulars	Key Management Personnel and Relatives	Subsidiary Comp	Other Entities	Total
<u>Receivables :</u>				
- Organic India Pvt. Ltd.			1,23,525 (1,45,593) (4,26,107) (5,18,620)	1,23,525 (1,45,593) (4,26,107) (5,18,620)
<u>Payables :</u>				
- Amit Sharma	NIL (NIL) (NIL) (7,500)	-	-	NIL (NIL) (NIL) (7,500)
- Wellness Products	-	-	NIL (NIL) (NIL) (19,36,797)	NIL (NIL) (NIL) (19,36,797)
- Organic India Pvt. Ltd.			51,56,776 (76,55,273) (80,74,659) (47,90,436)	51,56,776 (76,55,273) (80,74,659) (47,90,436)
- Organic India Pvt. Ltd. (Interest on Debentures payable)			2,55,48,891 (2,07,12,685) (1,07,98,756) (11,52,772)	2,55,48,891 (2,07,12,685) (1,07,98,756) (11,52,772)
Organic India Pvt. Ltd.			11,90,86,230	11,90,86,230



Sharma

R. Sharma

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

(Debentures)			(11,90,86,230)	(11,90,86,230)
			(11,90,86,230)	(11,90,86,230)
			(11,90,86,230)	(11,90,86,230)

Note: Figures in bracket represent previous year's figures.

35. The disclosures required under IND AS 19 "Employee Benefits" as given below:

A) Defined Contribution plan

The Company has classified the various benefits provided to employees' as follows:

- Defined Contribution Plans – Provident Fund
- Employee State Insurance Plan

Contribution to Defined Contribution Plan, recognized as expense for the Year is as under:

Particulars	(Amount in Rs)			
	As at 30 September, 2021	As at 31 March, 2021	As at 31 March, 2020	As at 31 March, 2019
Company's contribution to provident fund	5,95,014	11,99,340	16,95,668	1,33,157
Company's contribution to ESI	22,590	58,290	98,163	18,486

B) Defined Benefit Plan:

The employees' gratuity fund defined benefit plan. The present value of obligation is determined based on actuarial valuation using by projected unit credit method in case of gratuity.

- Reconciliation of opening and closing Balance of Defined Benefit Obligation

Particulars	As at 31st March, 2021		As at 31st March, 2020		As at 31st March, 2019	
	Gratuity	Earned Leave	Gratuity	Earned Leave	Gratuity	Earned Leave
Present value of obligation at the beginning of the year	9,383,185	2,873,434	6,056,816	1,935,587	4,777,977	1,748,178
Current service cost	2,131,162	1,658,421	2,220,162	965,215	1,298,938	600,564
Interest cost	649,316	198,842	463,952	148,266	372,682	136,358
Benefits paid	(1,758,641)	(419,284)	(163,384)	(262,909)	(485,977)	(438,956)
Actuarial loss/(gain)	-	1,460,729	805,639	87,275	93,196	(110,557)
Present value of obligation at the end of year	10,405,022	5,772,142	9,383,185	2,873,434	6,056,816	1,935,587



Mishra

R. Sharma

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

The components of the gratuity are as follows:

b) Expenses recognized statement of profit & loss account

(Amount in Rs)

Particulars	Year ended March 31, 2021		Year ended March 31, 2020		Year ended March 31, 2019	
	Gratuity	Earned Leave	Gratuity	Earned Leave	Gratuity	Earned Leave
Current service cost	21,31,162	16,58,421	22,20,162	9,65,215	12,98,938	6,00,564
Interest cost	6,49,316	1,98,842	4,63,952	1,48,266	3,72,682	1,36,358
Defined benefit cost recognized in statement of Profit or loss	27,80,478	18,57,263	26,84,114	11,13,481	16,71,620	7,36,922

c) Recognize in Other Comprehensive Income

(Amount in Rs)

Particulars	Year ended March 31, 2021		Year ended March 31, 2020		Year ended March 31, 2019	
	Gratuity	Earned Leave	Gratuity	Earned Leave	Gratuity	Earned Leave
Net Actuarial (Gain)/Loss	(17,58,641)	14,60,729	8,05,639	87,275	93,196	(1,10,557)

c) Bifurcation of PBO at the end of the year

(Amount in Rs)

Particulars	Year ended March 31, 2021		Year ended March 31, 2020		Year ended March 31, 2019	
	Gratuity	Earned Leave	Gratuity	Earned Leave	Gratuity	Earned Leave
Current Liability	6,31,728	4,08,877	5,11,394	1,97,468	3,66,565	1,44,104
Non-Current Liability	97,73,294	53,63,265	88,71,791	26,75,966	56,90,251	17,91,483

d) The principal actuarial assumptions used for estimating the Company's defined benefit obligations for gratuity and leave encashment are set out below:

(Amount in Rs)

Particulars	Year ended March 31, 2021		Year ended March 31, 2020		Year ended March 31, 2019	
	Gratuity	Earned Leave	Gratuity	Earned Leave	Gratuity	Earned Leave
Discount Rate	6.91	6.91	6.92	6.92	7.66	7.66
Salary Escalation	10	10	10	10	10	10
Withdrawal rate (Per Annum)						
Mortality	100% of IALM (2012 - 14)					

The Estimates of future salary increase considered in actuarial valuation, take account of inflation, seniority promotion and other relevant factors, such as supply and demand in the employment market. The above information is certified by the actuary.



Handwritten signature: Krishna

Handwritten signature: R. Sharma

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

e) Experience Adjustment:

(Amount in Rs.)

Particulars	Year ended March 31, 2021		Year ended March 31, 2020		Year ended March 31, 2019	
	Gratuity	Earned Leave	Gratuity	Earned Leave	Gratuity	Earned Leave
Actuarial (Gain)/Loss on plan obligation	(17,68,300)	14,55,022	2,10,563	(1,07,970)	21,125	(1,34,528)

f) Sensitivity Analysis

(Amount in Rs.)

Particulars	Change in Assumption	Year ended March 31, 2021		Year ended March 31, 2020		Year ended March 31, 2019	
		Gratuity	Earned Leave	Gratuity	Earned Leave	Gratuity	Earned Leave
Discount Rate	+0.5%	(4,73,048)	(2,72,203)	(4,29,408)	(1,33,810)	(2,60,960)	(83,411)
	-0.5%	5,12,150	2,99,624	465,245	1,47,274	2,81,502	89,819
Salary growth rate	+0.5%	4,57,867	2,86,742	3,97,177	1,40,992	2,73,998	87,426
	-0.5%	4,38,079	(2,67,754)	(3,80,949)	(1,31,606)	(2,56,732)	(82,057)

Sensitivities due to mortality & withdrawals are not material & hence impact of change due to these not calculated.

g) Maturity Profile of Declined Benefit Obligation (undiscounted)

	Year	Gratuity	Leave Encashment
a)	0 to 1 Year	-	-
b)	1 to 2 Year	-	-
c)	2 to 3 Year	-	-
d)	3 to 4 Year	-	-
e)	4 to 5 Year	-	-
f)	5 to 6 Year	-	-
g)	6 Year onwards	-	-

The management has provided for Gratuity and Leave Encashment for the period from April 2021 to September 2021 on the basis of estimation and assessment and Actuarial Valuation from Actuarial Valuer will be carried out the end of the Financial Year 2021-22.

36. Description of Risk Exposures:

Valuations are based on certain assumptions, which are dynamic in nature and vary over time. As such company is exposed to various risks as follow -

- Salary Increases- Actual salary increases will increase the Plan's liability. Increase in salary increase rate assumption in future valuations will also increase the liability.
- Investment Risk – If Plan is funded then assets liabilities mismatch & actual investment return on assets lower than the discount rate assumed at the last valuation date can impact the liability.
- Discount Rate : Reduction in discount rate in subsequent valuations can increase the plan's liability.
- Mortality & disability – Actual deaths & disability cases proving lower or higher than assumed in the valuation can impact the liabilities.



Handwritten signature/initials

Handwritten signature/initials

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

- E) Withdrawals – Actual withdrawals proving higher or lower than assumed withdrawals and change of withdrawal rates at subsequent valuations can impact Plan's liability.

37. Disclosure of Earning Per Share as per Ind AS-33.

(Amount in Rs.)

Particulars	For the Period ended September 30, 2021	For the year ended March 31, 2021	For the year ended March 31, 2020	For the year ended March 31, 2019
a) Profit for the year attributable to Equity Shareholders	(1,95,93,593)	(3,57,98,587)	(3,66,46,615)	(43,62,694)
b) Weighted average number of Equity Shares for Basic / Diluted EPS	21,171	21,171	21,171	21,171
c) Earnings per share of Rs. 10 each				
- Basic / Diluted	(925.49)	(1,690.93)	(1,730.98)	(206.07)

38. In the opinion of Board, all known liabilities and expenses have been fully provided for in the account.

39.

(a) In the opinion of Board, Current Assets, Loans & Advances shown in the Balance Sheet shall have a value on realization in the ordinary course of business at least equal to the amount at which they are stated.

(b) The Company is in process to develop in house software for providing online nutrition advisory services to its customers. The expenditure of Rs. 57,04,979 (Previous Year Rs. 1,24,56,382/-) incurred for development of the software is shown under "Intangible assets under development" and the management is confident to fully develop the software in due course of time.

40. Balances of Loans and Advances, other current liabilities and other personal accounts are subject to reconciliation/confirmation from the respective parties. The management does not expect any material differences affecting the financial statement for the year. The company has initiated action to further strengthen its internal control w.r.t sale of goods & service, balance confirmation/reconciliation.

41. The company is a Small and Medium Sized Company ("SMC") as defined in the general instructions in respect of Accounting Standards specified under Section 133 of the Companies Act, 2013 (Act) and Rule 7 of the Companies (Accounts) Rules, 2014. Accordingly, the Company has complied with Accounting Standards as applicable to a Small and Medium Sized Company.

42. The company has no material foreseeable losses which required provision under the applicable law or accounting standards on long term contracts. The company is not dealing in derivative contracts.

43. Financial Risk Management Objectives and Policies

The Company's activities are exposed to a variety of financial risks from its operations. The key financial risks include market risk (including interest rate risk and commodity price risk), credit risk and liquidity risk.

I. Market risk: Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises



[Signature]

[Signature]

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

mainly three types of risk: interest rate risk, currency risk and other price risk such as commodity price risk.

(a) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. However, the company is not exposed to any type of interest rate risk.

(b) Commodity Price Risk:

The Company is not foreseen any commodity price risk as company is not dealing any such kind of product, whose prices are fluctuating often in the market.

II. Credit risk

Credit risk is the risk that counterparty might not honor its obligations under a financial instrument or customer contract, leading to a financial loss. The company is exposed to credit risk from its operating activities (primarily trade receivables).

Trade Receivables:

Customer credit risk is managed based on company's established policy, procedures and controls. The company assesses the credit quality of the counterparties, taking into account their financial position, past experience and other factors. Credit risk is reduced by receiving pre-payments. The Company has a well-defined sales policy to minimize its risk of credit defaults. Company is collecting the package amount towards sale of its Medical Consultancy, Products, Academy and Blood Test Packages to customers in advance, however there is turnaround time of 7-10 days which payment gateway agencies normally takes to transfer the funds in Companies Bank Account. Company is regularly monitored the amount to be collected from the payment gateway agencies.

Deposits with Bank:

The deposits with banks constitute mostly the liquid investment of the company and are generally not exposed to credit risk.

Security Deposits:

The security deposits constitute mostly rental deposits paid by the company and are generally not exposed to credit risk.

Liquidity Risk:

Liquidity risk is the risk, where the company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The company's approach is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.



Shikha

(Amount in Rs.)

Shikha

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

Particulars	Upto 1 year	> 1 year
As at 30th September 2021		
Lease Liability	18,49,460	35,12,527
Borrowings	-	11,90,86,230
Trade Payables	52,47,761	-
Other Financial Liabilities	1,09,18,770	2,55,48,891
Total	1,80,15,991	14,81,47,648
As at 31st March 2021		
Lease Liability	-	78,909
Borrowings	-	11,90,86,230
Trade Payables	83,04,088	
Other Financial Liabilities	95,14,496	2,07,12,686
Total	1,78,18,584	13,98,77,825
As at 31st March 2020		
Lease Liability	13,77,742	31,32,832
Borrowings	-	11,90,86,230
Trade Payables	86,53,668	-
Other Financial Liabilities	89,77,466	1,07,98,757
Total	1,90,08,876	13,30,17,819
As at 31st March 2019		
Lease Liability	19,44,297	-
Borrowings	-	11,90,86,230
Trade Payables	40,01,857	-
Other Financial Liabilities	96,25,459	11,52,772
Total	1,55,71,615	12,02,39,002

44. Capital Risk Management

The Company's policy is to maintain an adequate capital base so as to maintain creditor and market confidence and to sustain future development. Capital includes issued capital and all other equity reserves attributable to equity shareholders. The primary objective of the Company's capital management is to maintain an optimal structure so as to maximize the shareholder's value. The Company determines the amount of capital required on the basis of annual operating plans and long-term product and other strategic investment plans. The funding requirements are met through equity, which is not subject to any externally imposed capital requirements. The capital structure of the company consists of equity.

45. Fair value of Financial Assets and Liabilities

Class wise composition of carrying amount and fair value of financial assets and liabilities that are recognized in the financial statements is given below:

(a) Financial Asset

(Amount in Rs.)



[Handwritten signature]

[Handwritten signature]

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

Particulars	September 30, 2021		March 31, 2021		March 31, 2020		March 31, 2019	
	Carrying Amount	Fair value	Carrying Amount	Fair value	Carrying Amount	Fair value	Carrying Amount	Fair value
<u>Financial assets designated at amortized cost:</u>								
Non-Current-Loans								
Current – Loan								
Cash and cash equivalents	7,747,908	7,747,908	11,856,817	11,856,817	66,419,525	66,419,525	95,969,710	95,969,710
Bank Balances Other	26,142,888	26,142,888	34,819,469	34,819,469	19,685,121	19,685,121	24,711,600	24,711,600
Trade and other receivables	207,437	207,437	268,863	268,863	429,507	429,507	945,043	945,043
Other financial assets	1,458,760	1,458,760	1,678,958	1,678,958	1,296,757	1,296,757	1,669,161	1,669,161
Investments								
Total	35,556,992	35,556,992	48,624,107	48,624,107	87,830,910	87,830,910	123,295,514	123,295,514

b). Financial Liabilities

(Amount in Rs.)

Particulars	September 30, 2021		March 31, 2021		March 31, 2020		March 31, 2019	
	Carrying Amount	Fair value	Carrying Amount	Fair value	Carrying Amount	Fair value	Carrying Amount	Fair value
<u>Financial liabilities designated at amortized cost</u>								
Lease Liability	1,849,460	1,849,460	-	-	1,377,742	1,377,742	-	-
Trade & other payables	5,247,761	5,247,761	8,304,088	8,304,088	8,653,668	8,653,668	4,001,857	4,001,857
Borrowings	119,086,230	119,086,230	119,086,230	119,086,230	119,086,230	119,086,230	119,086,230	119,086,230
Other financial liabilities	36,467,661	36,467,661	30,227,183	30,227,183	19,776,223	19,776,223	10,778,234	10,778,234
Total	162,651,112	162,651,112	157,617,501	157,617,501	148,893,863	148,893,863	133,866,320	133,866,320

46. Segment Reporting:

Company operates in a single operating segment i.e. Medical Advisory Services and its related products.



Shirka

Sharma

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

47. Due to outbreak of Covid-19 globally and in India, the Company temporarily closed its operations on March 23, 2020 to stop the spread of Covid-19 and to protect the health and safety of all. Further, the Company has carried out its initial assessment of the likely adverse impact on economic environment and financial risk because of Covid-19. The Company is in the business of Medical Advisory Services and its related products. Although, there is significant impact, on account of demand destruction, in the short term, however, management believes that there may not be significant impact of Covid-19 pandemic on the financial position and performance of the Company, in the long-term. The Company expects to recover the carrying amount of all its assets including inventories, receivables and loans in the ordinary course of business based on information available on current economic conditions. The Company is continuously monitoring any material change in future economic conditions.

48. The Company has adopted Ind AS 116 'Leases' w.e.f April 1, 2019 for the purpose of Reinstatement of Financials as required by SEBI. This has resulted in recognizing a Right-of-Use Asset and a corresponding Lease liability of Rs. 68,71,702/- as at April 1, 2019.

Particulars	(Amount in Rs.)			
	As at September 30, 2021	As at March 31, 2021	As at March 31, 2020	As at March 31, 2019
Right of Use Assets	64,303	42,67,432	68,71,702	-
Addition during the year	61,39,125	-	-	-
Deletion during the year	-	21,30,763	-	-
Amortization during the year	10,02,229	20,72,366	26,04,270	-
Net Book Value – End of Period	52,01,199	64,303	42,67,432	-
Lease Liability At the end of the Year	53,61,987	78,909	45,10,573	-

49. Effective 1st April, 2018, the Company has adopted Ind AS 115 'Revenue from contracts with customers: -

Accordingly, The Company satisfies a performance obligation and recognises revenue at a point of time.


There is insignificant impact on account of applying Ind AS 115 Revenue from Contract with customers instead of the erstwhile Ind AS 18 Revenue, on the financial statements of the Company.

A. Reconciliation of revenue from contracts with customer

Particulars	Amount in Rs.
Revenue from contract with customer as per the contract price	-
Adjustments made to contract price on account of:	-
Less: Sales Returns / Reversals	-
Revenue from contract with customer as per the Statement of Profit and Loss	-

B. Movement of Contract Liabilities

Particulars	(Amount in Rs.)			
	F.Y. 20-21	F.Y. 20-21	F.Y. 19-20	F.Y. 18-19
Opening Balance	84,39,116	1,14,48,382	1,68,41,120	1,66,82,384
Additions during the year (net)	1,25,30,257	84,39,116	1,14,48,382	1,68,41,120
Reclassification Adjustments:				
-Reclass of opening balances of contract liabilities to revenue	71,63,267	1,14,48,382	1,68,41,120	1,66,82,384
Closing balance	1,38,06,106	84,39,116	1,14,48,382	1,68,41,120



Handwritten signature/initials

Handwritten signature

NUTRIWEL HEALTH (INDIA) PRIVATE LIMITED
NOTES ON ACCOUNTS

50. On March 24, 2021, the Ministry of Corporate affairs (MCA) through a notification, amended schedule III of the Companies Act, 2013 and the amendments are applicable for financial period commencing from April 1, 2021.

Base on further amendments and clarifications to schedule III, if any, the disclosures will be updated in the period in which such guidance is issued.

The comparative information in compliance with schedule III amendments have been reclassified to make them comparable.

51. Previous year figures have been regrouped/ rearranged / recast wherever necessary to confirm to the current year presentation.


For Lodha & Co.
Chartered Accountants
Firm Registration No.301051E



(Gaurav Lodha)
Partner
M.No. 507462

Place: New Delhi
Date : 13/12/2021



For and behalf of Board
Nutriwel Health (India) Pvt. Ltd.


(Shikha Nehru Sharma)
Managing Director
(DIN: 00174409)


(Raj Sharma)
Director
(DIN:00186615)

